Limits...
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

Khan G, Brooks SE, Mills KI, Guinn BA - Biomark Cancer (2015)

Bottom Line: If discovered early (Stage I), there is a 90% chance of five-year survival.We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels.This may reflect the predominantly stage I ovarian cancer samples examined.

View Article: PubMed Central - PubMed

Affiliation: Department of Life Sciences, University of Bedfordshire, Park Square, Luton, Bedfordshire, UK.

ABSTRACT
Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue.

No MeSH data available.


Related in: MedlinePlus

Expression of PASD1 in ovarian cancer TMAs. Images show the PASD1 staining of representative ovarian cancer samples at various stages of the disease. Each sample is identified by a unique sample identifier, ie, OT1, OT2, OT3, etc, followed by disease stage as indicated by a roman numeral and an alphabetical letter, ie, Ia, Ib, etc. PASD1 expression was predominantly absent from the ovarian cancer tissues tested. CA125 was used as a comparator as it is the industry standard for the confirmation of a diagnosis of ovarian cancer. Cells only and isotype controls were used as negative controls and actin as a positive control. The single melanoma (skin tumor) sample on each TMA was used as a positive control for immunolabeling with the PASD1 antibodies. Skin tumor samples expressed higher levels of actin, CA125, and PASD1 but did not immunolabel when incubated with isotype control antibody. NATs and normal ovarian tissues (NTs) were also tested and were predominantly negative except for actin expression.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4539101&req=5

f2-bic-7-2015-031: Expression of PASD1 in ovarian cancer TMAs. Images show the PASD1 staining of representative ovarian cancer samples at various stages of the disease. Each sample is identified by a unique sample identifier, ie, OT1, OT2, OT3, etc, followed by disease stage as indicated by a roman numeral and an alphabetical letter, ie, Ia, Ib, etc. PASD1 expression was predominantly absent from the ovarian cancer tissues tested. CA125 was used as a comparator as it is the industry standard for the confirmation of a diagnosis of ovarian cancer. Cells only and isotype controls were used as negative controls and actin as a positive control. The single melanoma (skin tumor) sample on each TMA was used as a positive control for immunolabeling with the PASD1 antibodies. Skin tumor samples expressed higher levels of actin, CA125, and PASD1 but did not immunolabel when incubated with isotype control antibody. NATs and normal ovarian tissues (NTs) were also tested and were predominantly negative except for actin expression.

Mentions: The PASD1-1 antibody that immunolabeled PASD1a and b scored only 0 in normal adjacent ovarian tissue (NAT) and 0–1 in healthy ovarian tissue, whereas the PASD1-2 monoclonal antibody that immunolabels PASD1b had immunolabeling scores ranging 0–1 for healthy tissue and 0–2 for normal adjacent tissue (Table 2A and Fig. 2). Immunolabeling of normal endometrial tissue with the anti-PASD1b antibody was not observed (Table 2C), although CA125 was found to immunolabel some normal endometrial tissues.


Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

Khan G, Brooks SE, Mills KI, Guinn BA - Biomark Cancer (2015)

Expression of PASD1 in ovarian cancer TMAs. Images show the PASD1 staining of representative ovarian cancer samples at various stages of the disease. Each sample is identified by a unique sample identifier, ie, OT1, OT2, OT3, etc, followed by disease stage as indicated by a roman numeral and an alphabetical letter, ie, Ia, Ib, etc. PASD1 expression was predominantly absent from the ovarian cancer tissues tested. CA125 was used as a comparator as it is the industry standard for the confirmation of a diagnosis of ovarian cancer. Cells only and isotype controls were used as negative controls and actin as a positive control. The single melanoma (skin tumor) sample on each TMA was used as a positive control for immunolabeling with the PASD1 antibodies. Skin tumor samples expressed higher levels of actin, CA125, and PASD1 but did not immunolabel when incubated with isotype control antibody. NATs and normal ovarian tissues (NTs) were also tested and were predominantly negative except for actin expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4539101&req=5

f2-bic-7-2015-031: Expression of PASD1 in ovarian cancer TMAs. Images show the PASD1 staining of representative ovarian cancer samples at various stages of the disease. Each sample is identified by a unique sample identifier, ie, OT1, OT2, OT3, etc, followed by disease stage as indicated by a roman numeral and an alphabetical letter, ie, Ia, Ib, etc. PASD1 expression was predominantly absent from the ovarian cancer tissues tested. CA125 was used as a comparator as it is the industry standard for the confirmation of a diagnosis of ovarian cancer. Cells only and isotype controls were used as negative controls and actin as a positive control. The single melanoma (skin tumor) sample on each TMA was used as a positive control for immunolabeling with the PASD1 antibodies. Skin tumor samples expressed higher levels of actin, CA125, and PASD1 but did not immunolabel when incubated with isotype control antibody. NATs and normal ovarian tissues (NTs) were also tested and were predominantly negative except for actin expression.
Mentions: The PASD1-1 antibody that immunolabeled PASD1a and b scored only 0 in normal adjacent ovarian tissue (NAT) and 0–1 in healthy ovarian tissue, whereas the PASD1-2 monoclonal antibody that immunolabels PASD1b had immunolabeling scores ranging 0–1 for healthy tissue and 0–2 for normal adjacent tissue (Table 2A and Fig. 2). Immunolabeling of normal endometrial tissue with the anti-PASD1b antibody was not observed (Table 2C), although CA125 was found to immunolabel some normal endometrial tissues.

Bottom Line: If discovered early (Stage I), there is a 90% chance of five-year survival.We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels.This may reflect the predominantly stage I ovarian cancer samples examined.

View Article: PubMed Central - PubMed

Affiliation: Department of Life Sciences, University of Bedfordshire, Park Square, Luton, Bedfordshire, UK.

ABSTRACT
Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue.

No MeSH data available.


Related in: MedlinePlus